Shin Nippon Biomedical Laboratories, Ltd. (SBLOF)

Market Cap	326.63M -19.7%
Revenue (ttm)	208.66M +1.7%
Net Income	33.04M +6.1%
EPS	0.82 +6.1%
Shares Out	n/a
PE Ratio	11.75
Forward PE	n/a
Dividend	0.32 (3.29%)
Ex-Dividend Date	Sep 29, 2026

Volume	7,000
Open	9.60
Previous Close	n/a
Day's Range	9.60 - 10.00
52-Week Range	7.00 - 12.57
Beta	-0.20
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 10, 2026

About SBLOF

Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, engages in the pharmaceutical development, transactional research, and medipolis businesses in Japan and internationally. It offers non-clinical testing and non-clinical regulatory consulting for the development of pharmaceuticals, medical devices, or regenerative medicine products, including safety and pharmacology testing, and pharmacokinetic studies. The company also engages in licensing activities for proprietary products which utilize unique intranasal formulation...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1957
• Employees: 1,680
• Stock Exchange: OTCMKTS
• Ticker Symbol: SBLOF

Financial Performance

In fiscal year 2026, SBLOF's revenue was 32.52 billion, an increase of 0.34% compared to the previous year's 32.41 billion. Earnings were 4.57 billion, a decrease of -7.27%.

Financial numbers in JPY

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Nov 10, 2026

Data Sources Report a data error